UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended September 30, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from to
.
Commission
File Number: 001-39945
CONSTELLATION
ACQUISITION CORP I
(Exact
name of registrant as specified in its charter)
Cayman Islands | | 98-1574835 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
200 Park Avenue 32nd Floor New York, NY | | 10166 |
(Address of principal executive offices) | | (Zip Code) |
(646)
585-8975
(Registrant’s telephone number, including area code)
Not
Applicable
(Former
name, former address and formal fiscal year, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Class A ordinary shares, par value $0.0001 per share | | CSTAF | | OTCQX® Best Market |
Redeemable warrants, each one whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50 | | CSTWF | | OTCQB® Venture Market |
Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant | | CSTUF | | OTCQX® Best Market |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
As
of November 14, 2024, 9,967,684 Class A ordinary shares, par value $0.0001 per share, and 150,000 Class B ordinary shares, par value
$0.0001 per share, were issued and outstanding.
CONSTELLATION
ACQUISITION CORP I
Form 10-Q
For
the Quarter Ended September 30, 2024
Table
of Contents
PART
I. FINANCIAL INFORMATION
Item
1. Financial Statements.
CONSTELLATION
ACQUISITION CORP I
CONDENSED BALANCE SHEETS
| |
September 30, 2024 | | |
December 31, 2023 | |
| |
(Unaudited) | | |
| |
Assets: | |
| | |
| |
Current Assets: | |
| | |
| |
Cash | |
$ | 5,666 | | |
$ | 3,541 | |
Prepaid expenses | |
| 129,527 | | |
| 33,411 | |
Total current assets | |
| 135,193 | | |
| 36,952 | |
Cash held in Trust Account | |
| 27,686,372 | | |
| 49,857,596 | |
Total Assets | |
$ | 27,821,565 | | |
$ | 49,894,548 | |
| |
| | | |
| | |
Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 3,668,072 | | |
$ | 3,080,658 | |
Due to related party | |
| 210,000 | | |
| 120,000 | |
Promissory notes – related party | |
| 1,352,208 | | |
| 227,208 | |
Convertible promissory note - related party | |
| 3,181,000 | | |
| 3,131,000 | |
Total current liabilities | |
| 8,411,280 | | |
| 6,558,866 | |
Deferred underwriting fee | |
| 10,850,000 | | |
| 10,850,000 | |
Warrant liability | |
| 297,829 | | |
| 300,199 | |
Total Liabilities | |
| 19,559,109 | | |
| 17,709,065 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 6) | |
| | | |
| | |
Class A ordinary shares subject to possible redemption, 2,367,684 and 4,493,843 shares at redemption value at approximately $11.69 and $11.09 per share as of September 30, 2024 and December 31, 2023, respectively | |
| 27,686,372 | | |
| 49,857,596 | |
| |
| | | |
| | |
Shareholders’ Deficit: | |
| | | |
| | |
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 | |
| — | | |
| — | |
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 7,600,000 and no shares issued and outstanding (excluding 2,367,684 and 4,493,843 shares subject to possible redemption) as of September 30, 2024 and December 31, 2023, respectively | |
| 760 | | |
| — | |
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 150,000 and 7,750,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | |
| 15 | | |
| 775 | |
Additional paid-in capital | |
| — | | |
| — | |
Accumulated deficit | |
| (19,424,691 | ) | |
| (17,672,888 | ) |
Total Shareholders’ Deficit | |
| (19,423,916 | ) | |
| (17,672,113 | ) |
Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit | |
$ | 27,821,565 | | |
$ | 49,894,548 | |
The
accompanying notes are an integral part of these unaudited condensed financial statements.
CONSTELLATION
ACQUISITION CORP I
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
For the Three Months Ended
September 30, | | |
For the Nine Months Ended
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
General and administrative costs | |
$ | 244,972 | | |
$ | 731,336 | | |
$ | 1,259,173 | | |
$ | 2,358,175 | |
Loss from Operations | |
| (244,972 | ) | |
| (731,336 | ) | |
| (1,259,173 | ) | |
| (2,358,175 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income: | |
| | | |
| | | |
| | | |
| | |
Interest earned on investments held in Trust Account | |
| 310,320 | | |
| 553,975 | | |
| 1,005,309 | | |
| 2,460,396 | |
Change in fair value of warrant liability | |
| (27,649 | ) | |
| 484,270 | | |
| 2,370 | | |
| 31,600 | |
Total other income | |
| 282,671 | | |
| 1,038,245 | | |
| 1,007,679 | | |
| 2,491,996 | |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) | |
$ | 37,699 | | |
$ | 306,909 | | |
$ | (251,494 | ) | |
$ | 133,821 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares outstanding, redeemable Class A ordinary shares | |
| 2,367,684 | | |
| 4,493,843 | | |
| 2,584,956 | | |
| 7,018,239 | |
Basic and diluted net income (loss) per share, redeemable Class A ordinary shares | |
$ | 0.00 | | |
$ | 0.03 | | |
$ | (0.02 | ) | |
$ | 0.01 | |
Weighted average shares outstanding,
non-redeemable Class A ordinary shares and Class B ordinary shares | |
| 7,750,000 | | |
| 7,750,000 | | |
| 7,750,000 | | |
| 7,750,000 | |
Basic and diluted net
income (loss) per share, non-redeemable Class A ordinary shares and Class B ordinary shares | |
$ | 0.00 | | |
$ | 0.03 | | |
$ | (0.02 | ) | |
$ | 0.01 | |
The
accompanying notes are an integral part of these unaudited condensed financial statements.
CONSTELLATION
ACQUISITION CORP I
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(UNAUDITED)
FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
| |
Non-Redeemable Class A Ordinary Shares | | |
Class B Ordinary shares | | |
Additional Paid-In | | |
Accumulated | | |
Total Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance as of January 1, 2024 (audited) | |
| — | | |
$ | — | | |
| 7,750,000 | | |
$ | 775 | | |
$ | — | | |
$ | (17,672,888 | ) | |
$ | (17,672,113 | ) |
Accretion of Class A ordinary shares subject to redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (553,991 | ) | |
| (553,991 | ) |
Conversion of Class B ordinary shares to Class A ordinary shares | |
| 7,600,000 | | |
| 760 | | |
| (7,600,000 | ) | |
| (760 | ) | |
| — | | |
| — | | |
| — | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (494,150 | ) | |
| (494,150 | ) |
Balance as of March 31, 2024 | |
| 7,600,000 | | |
$ | 760 | | |
| 150,000 | | |
$ | 15 | | |
$ | — | | |
$ | (18,721,029 | ) | |
$ | (18,720,254 | ) |
Accretion of Class A ordinary shares subject to redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (470,998 | ) | |
| (470,998 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 204,957 | | |
| 204,957 | |
Balance as of June 30, 2024 | |
| 7,600,000 | | |
$ | 760 | | |
| 150,000 | | |
$ | 15 | | |
$ | — | | |
$ | (18,987,070 | ) | |
$ | (18,986,295 | ) |
Accretion of Class A ordinary shares subject to redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (475,320 | ) | |
| (475,320 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 37,699 | | |
| 37,699 | |
Balance as of September 30, 2024 | |
| 7,600,000 | | |
$ | 760 | | |
| 150,000 | | |
$ | 15 | | |
$ | — | | |
$ | (19,424,691 | ) | |
$ | (19,423,916 | ) |
FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023
| |
Class B Ordinary Shares | | |
Additional Paid-in | | |
Accumulated | | |
Total Shareholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance as of January 1, 2023 (audited) | |
| 7,750,000 | | |
$ | 775 | | |
$ | — | | |
$ | (12,486,354 | ) | |
$ | (12,485,579 | ) |
Accretion of Class A ordinary shares subject to redemption | |
| — | | |
| — | | |
| — | | |
| (1,819,906 | ) | |
| (1,819,906 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (959,558 | ) | |
| (959,558 | ) |
Balance as of March 31, 2023 | |
| 7,750,000 | | |
$ | 775 | | |
$ | — | | |
$ | (15,265,818 | ) | |
$ | (15,265,043 | ) |
Accretion of Class A ordinary shares subject to redemption | |
| — | | |
| — | | |
| — | | |
| (986,515 | ) | |
| (986,515 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| 786,470 | | |
| 786,470 | |
Balance as of June 30, 2023 | |
| 7,750,000 | | |
$ | 775 | | |
$ | — | | |
$ | (15,465,863 | ) | |
$ | (15,465,088 | ) |
Accretion of Class A ordinary shares subject to redemption | |
| — | | |
| — | | |
| — | | |
| (1,003,975 | ) | |
| (1,003,975 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| 306,909 | | |
| 306,909 | |
Balance as of September 30, 2023 | |
| 7,750,000 | | |
$ | 775 | | |
$ | — | | |
$ | (16,162,929 | ) | |
$ | (16,162,154 | ) |
The
accompanying notes are an integral part of these unaudited condensed financial statements.
CONSTELLATION
ACQUISITION CORP I
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
For the Nine Months Ended September 30, | |
| |
2024 | | |
2023 | |
Cash Flows from Operating Activities: | |
| | |
| |
Net (loss) income | |
$ | (251,494 | ) | |
$ | 133,821 | |
Adjustments to reconcile net (loss) income to net cash used in operating activities: | |
| | | |
| | |
Interest earned on investments held in Trust Account | |
| (1,005,309 | ) | |
| (2,460,396 | ) |
Change in fair value of warrant liability | |
| (2,370 | ) | |
| (31,600 | ) |
Changes in operating assets and liabilities: | |
| | | |
| | |
Prepaid expenses | |
| (96,116 | ) | |
| (123,942 | ) |
Accounts payable and accrued expenses | |
| 587,414 | | |
| 1,391,187 | |
Due to related party | |
| 90,000 | | |
| 90,000 | |
Net cash used in operating activities | |
| (677,875 | ) | |
| (1,000,930 | ) |
| |
| | | |
| | |
Cash Flows from Investing Activities: | |
| | | |
| | |
Investment of cash in Trust Account | |
| (495,000 | ) | |
| (1,350,000 | ) |
Cash withdrawn from Trust Account in connection with redemption | |
| 23,671,533 | | |
| 269,485,746 | |
Net cash provided by investing activities | |
| 23,176,533 | | |
| 268,135,746 | |
| |
| | | |
| | |
Cash Flows from Financing Activities: | |
| | | |
| | |
Payments on promissory note to related party | |
| — | | |
| (31,572 | ) |
Proceeds from promissory note to related party | |
| 1,125,000 | | |
| — | |
Proceeds from convertible promissory note to related party | |
| 50,000 | | |
| 2,346,000 | |
Redemption of Class A ordinary shares | |
| (23,671,533 | ) | |
| (269,485,746 | ) |
Net cash used in financing activities | |
| (22,496,533 | ) | |
| (267,171,318 | ) |
| |
| | | |
| | |
Net change in cash | |
| 2,125 | | |
| (36,502 | ) |
Cash, beginning of the period | |
| 3,541 | | |
| 37,743 | |
Cash, end of the period | |
$ | 5,666 | | |
$ | 1,241 | |
The
accompanying notes are an integral part of these unaudited condensed financial statements.
CONSTELLATION
ACQUISITION CORP I
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
SEPTEMBER
30, 2024
Note
1 — Organization and Business Operations
Constellation
Acquisition Corp I (the “Company”) is a blank check company incorporated in the Cayman Islands on November 20, 2020. The
Company was formed for the purpose of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization or
similar business combination with one or more businesses (a “Business Combination”).
As
of September 30, 2024, the Company had not commenced any operations. All activity through September 30, 2024 relates to the Company’s
formation and the initial public offering (the “IPO” or “Initial Public Offering”) which is described below,
and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion
of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds
derived from the IPO.
The registration
statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on
January 26, 2021 (the “Effective Date”). On January 29, 2021, the Company consummated the IPO of 31,000,000 units
(the “Units” and, with respect to the Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”),
included in the Units sold, the “Public Shares”), including 1,000,000 Units issued pursuant to the partial
exercise of the underwriters’ over-allotment option, at $10.00 per Unit, generating gross proceeds of $310,000,000, which
is discussed in Note 3. Each Unit consists of one Class A ordinary share, and one-third of one redeemable warrant to purchase one Class
A ordinary share at a price of $11.50 per whole share.
Simultaneously
with the closing of the IPO, the Company consummated the sale of 5,466,667 private placement warrants (the “Private Placement
Warrants”), at a price of $1.50 per Private Placement Warrant, in a private placement to certain affiliates of the Company’s
sponsor at the time, Constellation Sponsor GmbH & Co. KG, a German limited partnership (the “Old Sponsor”),
generating gross proceeds of $8,200,000, which is discussed in Note 4.
Transaction
costs of the IPO amounted to $17,586,741, consisting of $6,200,000 of underwriting fees, $10,850,000 of deferred underwriting
fees (the “Deferred Underwriting Fees”), and $536,741 of other offering costs.
Following
the closing of the IPO on January 29, 2021, $310,000,000 ($10.00 per Unit) from the net offering proceeds of the sale of the
Units in the IPO and the sale of the Private Placement Warrants was placed in a Company trust account (the “Trust Account”)
and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company
Act of 1940, as amended, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated
under the Investment Company Act which invest only in direct U.S. government treasury obligations. Except with respect to interest
earned on the funds held in the Trust Account that may be released to the Company to pay the income taxes, if any, the Company’s
amended and restated memorandum and articles of association (the “amended and restated memorandum and articles of association”)
will provide that the proceeds from the IPO and the sale of the Private Placement Warrants held in the Trust Account will not be released
from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders,
until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary
shares that such shareholders properly elected to redeem, subject to the limitations, (b) the redemption of any Public Shares properly
tendered in connection with a (A) shareholder vote to amend the amended and restated memorandum and articles of association to modify
the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares
redeemed in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete
the initial Business Combination by the date by which the Company is required to consummate a Business Combination pursuant to the Company’s
amended and restated memorandum and articles of association (such period, the “Combination Period”), or (B) with respect
to any other provision relating to the rights of holders of the Class A ordinary shares or pre-initial Business Combination activity,
and (c) the redemption of the Public Shares if the Company has not consummated the initial Business Combination within the Combination
Period. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in
the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination
or liquidation if the Company has not consummated an initial Business Combination within the Combination Period, with respect to such
Class A ordinary shares so redeemed.
The
proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have
priority over the claims of the public shareholders.
The
Company will provide its public shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion
of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination
or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business
Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem
their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per share, plus
any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations).
If
the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except
for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten (10) business days, redeem the Public Shares,
at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned
on the funds held in the Trust Account and not previously released to the Company to pay the income taxes, if any, divided by the number
of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders
(including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of the remaining shareholders and the Company’s board of directors (the “Board”),
liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the obligations under Cayman Islands law to provide for claims
of creditors and the requirements of other applicable law.
There
will be no redemption rights or liquidating distributions with respect to the Private Placement Warrants, which will expire worthless
if the Company fails to consummate an initial Business Combination within the Combination Period.
The
Sponsor, officers and directors have agreed to waive their redemption rights with respect to their Founder Shares (as defined below)
and any Public Shares purchased during or after the IPO in connection with (i) the completion of the initial Business Combination, (ii)
a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association, and (iii)
waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete
its initial Business Combination within the Combination Period.
The
Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services
rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of
intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below
the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the
liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable,
provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any
and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under
the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities
Act of 1933, as amended (the “Securities Act”). However, the Company has not asked its Sponsor to reserve for such indemnification
obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations
and believe that the Company’s Sponsor’s only assets are Securities of the Company. Therefore, the Company cannot assure
that its Sponsor would be able to satisfy those obligations.
On
January 26, 2023, the Old Sponsor underwent a reorganization pursuant to which the limited partners of the Old Sponsor transferred all
of their limited partnership interests to Constellation Sponsor LP, a Delaware limited partnership (the “Sponsor”). On January
26, 2023, the Old Sponsor liquidated pursuant to applicable law by the retirement of the general partner of the Old Sponsor (the second
to last partner of the Sponsor) and all Securities held by the Old Sponsor were distributed by operation of law to its sole remaining
limited partner, the Sponsor, following which, on January 30, 2023, control of the Sponsor was transferred to affiliates of Antarctica
Capital Partners, LLC, including Antarctica Endurance Manager, LLC the current general partner of the Sponsor.
On
January 27, 2023, the Company held an extraordinary general meeting of shareholders of the Company (the “Extension Meeting”)
to amend the Company’s amended and restated memorandum and articles of association (the “2023 Articles Amendment”)
to extend the date by which the Company has to consummate a Business Combination from January 29, 2023 (the “2023 Original Termination
Date”) to April 29, 2023 (the “2023 Articles Extension Date”) and to allow the Company, without another shareholder
vote, to elect to extend the Termination Date to consummate a Business Combination on a monthly basis for up to nine times by an additional
one month each time after the 2023 Articles Extension Date, by resolution of the Company’s Board if requested by the Sponsor, and
upon five days’ advance notice prior to the applicable Termination Date, or a total of up to twelve (12) months after the 2023
Original Termination Date, unless the closing of the Company’s initial Business Combination shall have occurred prior to such date
(the “2023 Extension Amendment Proposal”). Upon each of the nine one-month extensions, the Sponsor or one or more of its
affiliates, members or third-party designees may contribute to the Company $150,000 as a loan to be deposited into the Trust Account.
The shareholders of the Company approved the 2023 Extension Amendment Proposal at the Extension Meeting and on January 31, 2023, the
Company filed the 2023 Articles Amendment with the Registrar of Companies of the Cayman Islands. In connection with the Extension Meeting,
on January 30, 2023, the Company issued an unsecured promissory note, in the amount of $3,000,000 to the Sponsor (the “Extension
Note”).
In
connection with the vote to approve the 2023 Extension Amendment Proposal, the holders of 26,506,157 Class A ordinary shares of the Company
properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.17 per share, for an aggregate
redemption amount of approximately $269,485,746.
On
April 28, 2023, May 26, 2023, July 3, 2023, July 28, 2023, August 29, 2023, September 29, 2023, October 26, 2023, November 28, 2023 and
December 28, 2023, the Company drew $150,000 on each date, as approved by unanimous director resolution, dated April
24, 2023, pursuant to the Extension Note, which funds the Company deposited into the Trust Account for its public shareholders. This
deposit enabled the Company to extend the date by which it must complete its initial Business Combination from April 29, 2023 to January
29, 2024. These extensions are nine one-month extensions permitted under the amended and restated memorandum and articles of association
and provides the Company with additional time to complete its initial Business Combination. The Extension Note does not bear interest
and matures upon closing of the Company’s initial Business Combination. In the event that the Company does not consummate a Business
Combination, the Extension Note will be repaid only from amounts remaining outside of the Trust Account, if any.
On
December 20, 2023, the Company announced its intention to voluntarily delist its Class A ordinary shares, redeemable warrants, each one
whole warrant exercisable for one share of Class A ordinary shares at an exercise price of $11.50 (the “Public Warrants”)
and Units (collectively, the “Securities”) from the New York Stock Exchange (“NYSE”) and its intention to make
an application to have its Securities quoted on the OTCQX Marketplace (“OTCQX”).
The
Board approved the voluntary delisting on December 20, 2023, and the Company provided notice of the voluntary delisting to NYSE on December
20, 2023. The Company filed a Form 25 with the SEC to effect the delisting of its Securities on January 2, 2024. The delisting became
effective on January 12, 2024 when the Form 25 took effect. The last day of trading of its Securities on NYSE was January 12, 2024, and
the Securities were suspended pre-market on January 16, 2024. On January 16, 2024, the Company’s Securities began trading on the
OTCQX where the Class A ordinary shares and Units began trading on the OTCQX® Best Market under their new trading symbols
“CSTAF” and “CSTUF,” respectively, and the warrants started trading on the OTCQB® Venture Market
under its new trading symbol “CSTWF.” In connection with the extraordinary general meeting of the shareholders on January
29, 2024 (the “Shareholder Meeting”) the Company adhered to the initial or continued trading requirements of OTCQX.
On
January 23, 2024 and January 25, 2024, the Company held extraordinary general meetings and only voted on the Adjournment Proposal (as
defined below) to adjourn the Shareholder Meeting to January 25, 2024 and January 29, 2024, respectively. On January 29, 2024, the Company
held its Shareholder Meeting (A) to amend, by way of special resolution, the Company’s amended and restated memorandum and articles
of association (the “2024 Articles Amendment”) to extend the date (the “Termination Date”) by which the Company
has to consummate a Business Combination from January 29, 2024 (the “2024 Original Termination Date”) to February 29, 2024
(the “Articles Extension Date”) and to allow the Company, without another shareholder vote, to elect to extend the Termination
Date to consummate a Business Combination on a monthly basis for up to eleven (11) times by an additional one month each time after the
Articles Extension Date, by resolution of the Board, if requested by the Sponsor, and upon five days’ advance notice prior to the
applicable Termination Date, until January 29, 2025, or a total of up to twelve (12) months after the 2024 Original Termination Date,
unless the closing of a Business Combination shall have occurred prior thereto (the “2024 Extension Amendment Proposal”);
(B) to amend, by way of special resolution, the amended and restated memorandum and articles of association to eliminate the limitation
that the Company may not redeem Class A ordinary shares, to the extent that such redemption would result in the Company having net tangible
assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended), of less than $5,000,001
(the “Redemption Limitation”) in order to allow the Company to redeem Class A ordinary shares irrespective of whether such
redemption would exceed the Redemption Limitation (such proposal the “Redemption Limitation Amendment Proposal”); and (C)
if required, an adjournment proposal to adjourn, by way of ordinary resolution, the Shareholder Meeting to a later date or dates, if
necessary, (i) to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Shareholder Meeting,
there are insufficient ordinary shares (as defined below) in the capital of the Company represented (either in person or by proxy) to
approve the 2024 Extension Amendment Proposal and the Redemption Limitation Amendment Proposal, (ii) where the Company would not adhere
to the initial or continued trading requirements of OTCQX or (iii) where the Board has determined it is otherwise necessary (the “Adjournment
Proposal”).
The
shareholders of the Company approved the 2024 Extension Amendment Proposal and the Redemption Limitation Amendment Proposal at the Shareholder
Meeting and on January 30, 2024, the Company filed the 2024 Articles Amendment with the Registrar of Companies of the Cayman Islands,
effective January 29, 2024.
In
connection with the vote to approve the 2024 Extension Amendment Proposal and the Redemption Limitation Amendment Proposal, the holders
of 2,126,159 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately
$11.13 per share, for an aggregate redemption amount of approximately $23,671,533. After the satisfaction of such redemptions and receipt
of the initial deposit of $55,000 to the Trust Account, the balance in the Trust Account was approximately $26,415,545 after the redemptions
and initial deposit.
On
January 30, 2024, the Sponsor converted an aggregate of 7,600,000 Class B ordinary shares, par value $0.0001 per share (the “Class
B ordinary shares” and together with the Class A ordinary shares, the “ordinary shares”) into Class A ordinary shares
on a one-for-one basis. The Sponsor waived any right to receive funds from the Trust Account with respect to the Class A ordinary shares
received upon such conversion and acknowledged that such shares will be subject to all of the restrictions applicable to the original
Class B ordinary shares under the terms of that certain letter agreement, dated as of January 26, 2021 (the “Letter Agreement”),
by and among the Company and its initial shareholders, directors and officers (as further amended by and among, the Company, its directors
and officers, the Sponsor and other parties thereto, on January 30, 2023). As of January 30, 2024, there were 9,967,684 Class A ordinary
shares outstanding which were composed of 7,600,000 non-redeemable Class A ordinary shares and 2,367,684 redeemable Class A ordinary
shares.
In
connection with the Shareholder Meeting, the Sponsor agreed that the Sponsor (or one or more of its affiliates, members or third-party
designees) (the “Lender”) shall make a deposit into the Trust Account established in connection with the Company’s
Initial Public Offering of $55,000, in exchange for a non-interest bearing, unsecured promissory note issued by the Company to the Lender.
In addition, in the event that the Company has not consummated an initial Business Combination by February 29, 2024, without approval
of the Company’s public shareholders, the Company may, by resolution of the Company’s Board, if requested by the Sponsor,
and upon five days’ advance notice prior to the applicable Termination Date, extend the Termination Date up to eleven (11) times,
each by one additional month (for a total of up to eleven (11) additional months to complete a Business Combination), provided that the
Lender will deposit $55,000 into the Trust Account for each such monthly extension, for an aggregate deposit of up to $605,000 (if all
eleven (11) additional monthly extensions are exercised), in exchange for a non-interest bearing, unsecured promissory note issued by
the Company to the Lender.
On February 29, 2024 (“First 2024 Extension”),
March 28, 2024 (“Second 2024 Extension”), April 29, 2024 (“Third 2024 Extension”), May 29, 2024 (“Fourth
2024 Extension”), June 28, 2024 (“Fifth 2024 Extension”), July 23, 2024 (“Sixth 2024 Extension”), August
23, 2024 (“Seventh 2024 Extension”), September 26, 2024 (“Eighth 2024 Extension”) and October 29, 2024 (“Ninth
2024 Extension”), the Company drew $55,000 (the “Extension Funds”) on each date, as approved by unanimous director resolution,
dated February 27, 2024 pursuant to the Extension Note, which Extension Funds the Company deposited into the Trust Account for its public
shareholders. The deposit enabled the Company to extend the date by which it must complete its initial Business Combination from February
29, 2024 to November 29, 2024. These extensions are nine one-month extensions permitted under the amended and restated memorandum and
articles of association and provides the Company with additional time to complete its initial Business Combination. The 2024 Note does
not bear interest and matures upon closing of the Company’s initial Business Combination. In the event that the Company does not
consummate a Business Combination, the 2024 Note will be repaid only from amounts remaining outside of the Trust Account, if any.
Risks
and Uncertainties
Management
acknowledges that the Company depends on a variety of U.S. and multi-national financial institutions for banking services. Market conditions
can impact the viability of these institutions, which in effect will affect the Company’s ability to maintain and provide assurances
that the Company can access its cash and cash equivalents in a timely manner or at all. Any inability to access or delay in accessing
these funds could adversely affect the Company’s liquidity, business and financial condition.
In
February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action,
various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further,
the impact of this action and related sanctions on the world economy is not determinable as of the date of these unaudited condensed
financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not
determinable as of the date of these unaudited condensed financial statements.
In
October 2023, the Israel-Hamas war commenced. As a result of the war, instability in the Middle East and various other regions of the
world may occur and effect the world economy. Various nations, including the United States, as a reaction to the Israel-Hamas war have
begun taking actions that may further affect the world economy. Such effects on the world economy are not determinable as of the date
of these unaudited condensed financial statements. The specific impact on the Company’s financial condition, results of operations
and cash flows is also not determinable as of the date of these unaudited condensed financial statements.
Liquidity
and Going Concern Consideration
As
of September 30, 2024, the Company had $5,666 in its operating bank account and a working capital deficit of $5,095,087, net of the convertible promissory note – related party. Convertible promissory note - related party amounting to $3,181,000 is
not expected to be settled out of the current assets.
The
Company is within 12 months of its mandatory liquidation as of the time of filing this Quarterly Report on Form 10-Q. In connection with
the Company’s assessment of going concern considerations in accordance with Accounting Standards Update 2014-15, “Disclosures
of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the liquidity condition and mandatory liquidation
raise substantial doubt about the Company’s ability to continue as a going concern until the earlier of the consummation of the
Business Combination or the Termination Date.
These
unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification
of the liabilities that might be necessary should the Company be unable to continue as a going concern.
As
such, management plans to consummate a Business Combination prior to the mandatory liquidation date. If the Company’s estimates
of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than
the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial Business
Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination or because
it becomes obligated to redeem a significant number of its Public Shares upon completion of an initial Business Combination, in which
case the Company may issue additional securities or incur debt in connection with such initial Business Combination.
Note
2 — Significant Accounting Policies
Basis
of Presentation
The
accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally
accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of
the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited
condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement
of the balances and results for the periods presented. The interim results for the three and nine months ended September 30, 2024 are
not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any future period.
The
accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto
included in the Annual Report on Form 10-K filed by the Company with the SEC on March 29, 2024 (the “Annual Report”).
Emerging
Growth Company Status
The
Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of
such extended transition period which means that when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another
public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition
period difficult or impossible because of the potential differences in accounting standards used.
Use
of Estimates
The
preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited
condensed financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results could differ
from those estimates.
Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management
considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant
accounting estimates included in these unaudited condensed financial statements is the determination of the fair value of the warrant
liability and convertible promissory notes. Such estimates may be subject to change as more current information becomes available and,
accordingly, the actual results could differ significantly from those estimates.
Cash
The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did not have any cash equivalents as of September 30, 2024 and December 31, 2023.
Cash
Held in Trust Account
At
September 30, 2024 and December 31, 2023, the assets held in the Trust Account were held in a bank deposit account. During the period
ended September 30, 2024, the Company withdrew $23,671,533 from the Trust Account in connection with the redemption.
Concentration
of Credit Risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts and a Trust Account in a financial
institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack
of access to such funds could have a significant adverse impact on the Company’s financial condition.
Warrant
Liabilities
The Company evaluated the Public Warrants and Private
Placement Warrants (collectively, “Warrants,” which are discussed in Notes 3, 4, and 8) in accordance with Accounting Standards
Codification (“ASC”) 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” (“ASC
815-40”), and concluded that a provision in the warrant agreement, dated January 26, 2021, related to certain tender or exchange
offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as
contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the condensed balance sheets and measured at fair value
at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement” (“ASC
820”), with changes in fair value recognized in the condensed statements of operations in the period of change.
Convertible
Promissory Note
The
Company analyzed the convertible promissory notes to assess if the fair value option was appropriate, due to the substantial premium
which results in an offsetting entry to additional paid-in capital and under the related party guidance which precludes the fair value
option, it was determined the fair value option was not appropriate. As such, the Company accounted for the convertible promissory notes,
analyzing the conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate
conversion options embedded in convertible notes from their host instruments and to account for them as freestanding derivative financial
instruments.
Bifurcated
embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value
reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments
that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all
the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually
resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible
debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest
expense.
It
was determined that the conversion option was de minimis, as such the Company has recorded the Convertible Promissory Notes at par value.
Offering
Costs Associated with the Initial Public Offering
The
Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees
and other costs incurred through the IPO that were directly related to the IPO. Offering costs are allocated to the separable financial
instruments issued in the IPO based on a relative fair value basis, compared to total proceeds received. Offering costs associated with
warrant liabilities are expensed as incurred, presented as non-operating expenses in the condensed statements of operations. Transaction
costs amounted to $17,586,741, of which $1,143,138 was allocated to expense associated with the warrant liability. Offering costs
associated with the Class A ordinary shares were charged to temporary equity upon the completion of the IPO.
Class
A Ordinary Shares Subject to Possible Redemption
All
of the 31,000,000 Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for
the redemption of such Public Shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer
in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated memorandum
and articles of association. In accordance with the SEC and its staff’s guidance on redeemable equity instruments, which has been
codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption
to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the
entity’s equity instruments, are excluded from the provisions of ASC 480. Accordingly, at September 30, 2024 and December 31, 2023,
2,367,684 and 4,493,843 Class A ordinary shares subject to possible redemption were presented as temporary equity, outside of the
shareholders’ deficit section of the Company’s condensed balance sheets, respectively.
The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the Class A ordinary shares
subject to possible redemption to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying
amount of the Class A ordinary shares subject to possible redemption are affected by charges against additional paid-in capital and accumulated
deficit.
The
Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets as of September 30, 2024 and December
31, 2023 are reconciled in the following table:
Class A ordinary shares subject to possible redemption as of December 31, 2022 | |
$ | 314,517,268 | |
Less: | |
| | |
Redemptions | |
| (269,485,746 | ) |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 4,826,074 | |
Class A ordinary shares subject to possible redemption as of December 31, 2023 | |
$ | 49,857,596 | |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 553,991 | |
Less: | |
| | |
Redemptions | |
| (23,671,533 | ) |
Class A ordinary shares subject to possible redemption as of March 31, 2024 | |
$ | 26,740,054 | |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 470,998 | |
Class A ordinary shares subject to possible redemption as of June 30, 2024 | |
$ | 27,211,052 | |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 475,320 | |
Class A ordinary shares subject to possible redemption as of September 30, 2024 | |
$ | 27,686,372 | |
Income
Taxes
ASC
740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions
taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be
sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2024 and December 31, 2023.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of
interest and penalties as of September 30, 2024 and December 31, 2023. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax
examinations by major taxing authorities since inception.
The
Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently
not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s
tax provision was zero for the periods presented. The Company’s management does not expect that the total amount of unrecognized
tax benefits will materially change over the next twelve (12) months.
Net
Income (Loss) per Ordinary Share
The
Company complies with accounting and disclosure requirements of the Financial Accounting Standards Board ASC Topic 260, “Earnings
Per Share.” Net loss per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding
during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in
the IPO and the private placement to purchase an aggregate of 15,800,000 Class A ordinary shares (the “Private Placement”)
in the calculation of diluted net income (loss) per ordinary share, since the exercise of the Warrants are contingent upon the occurrence
of future events. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share
for the periods presented.
Basic
and diluted net income (loss) per ordinary share for Class A ordinary shares and Class B ordinary shares is calculated by dividing net
income attributable to the Company by the weighted average number of Class A ordinary shares and Class B ordinary shares outstanding,
allocated proportionally to each class of ordinary shares. This presentation assumes a Business Combination as the most likely outcome.
Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates
fair value.
Reconciliation
of Net Income (Loss) per Ordinary Share
The
Company’s condensed statements of operations include a presentation of net income (loss) per share for ordinary shares subject
to redemption in a manner similar to the two-class method of net income (loss) per share. Accordingly, basic and
diluted net income (loss) per redeemable Class A ordinary shares and non-redeemable Class A ordinary shares and B ordinary shares is
calculated as follows:
| |
For the Three Months
Ended September
30, | | |
For the Nine Months
Ended September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Redeemable Class A ordinary shares | |
| | |
| | |
| | |
| |
Allocation of net income (loss) to redeemable Class A ordinary shares subject to possible redemption | |
$ | 8,822 | | |
$ | 112,644 | | |
$ | (62,903 | ) | |
$ | 63,595 | |
Weighted average redeemable Class A ordinary shares subject to possible redemption | |
| 2,367,684 | | |
| 4,493,843 | | |
| 2,584,956 | | |
| 7,018,239 | |
Basic and diluted net income (loss) per share | |
$ | 0.00 | | |
$ | 0.03 | | |
$ | (0.02 | ) | |
$ | 0.01 | |
| |
| | | |
| | | |
| | | |
| | |
Non-redeemable Class A ordinary shares and B ordinary shares | |
| | | |
| | | |
| | | |
| | |
Allocation of net income (loss) to non-redeemable Class A ordinary shares and Class B ordinary shares | |
$ | 28,877 | | |
$ | 194,265 | | |
$ | (188,591 | ) | |
$ | 70,226 | |
Weighted average non-redeemable Class A ordinary shares and Class B ordinary shares | |
| 7,750,000 | | |
| 7,750,000 | | |
| 7,750,000 | | |
| 7,750,000 | |
Basic and diluted net income (loss) per share | |
$ | 0.00 | | |
$ | 0.03 | | |
$ | (0.02 | ) | |
$ | 0.01 | |
Fair
Value of Financial Instruments
The
Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each
reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.
The
fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities:
|
Level 1 — |
Valuations
based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and
regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. |
|
|
|
|
Level
2 — |
Valuations
based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active
for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived
principally from or corroborated by market through correlation or other means. |
|
|
|
|
Level
3 — |
Valuations
based on inputs that are unobservable and significant to the overall fair value measurement. |
The
fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820 (other than warrant
liability), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term
nature.
See
Note 8 for additional information on assets and liabilities measured at fair value on a recurring basis.
Recent
Accounting Pronouncements
The
Company’s management does not believe that any recently issued, but not effective, accounting standards, if currently adopted,
would have a material effect on the accompanying unaudited condensed financial statements.
Note
3 — Initial Public Offering
Public
Units
On
January 29, 2021, the Company sold 31,000,000 Units, at a purchase price of $10.00 per Unit, including 1,000,000 Units issued pursuant
to the partial exercise of the underwriters’ over-allotment option. Each Unit consists of one Class A ordinary share, and one-third
of one redeemable warrant to purchase one Class A ordinary share.
Public
Warrants
Each
whole warrant will entitle the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment.
Each warrant will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from
the closing of the IPO and will expire five years after the completion of the initial Business Combination, or earlier upon redemption
or liquidation.
The
Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation
to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares
underlying the warrants is then effective and a prospectus relating thereto is current, or a valid exemption from registration is available.
No warrant will be exercisable, and the Company will not be obligated to issue a Class A ordinary share upon exercise of a warrant, unless
the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities
laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding
sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such
warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event
that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have
paid the full purchase price for the unit solely for the Class A ordinary share underlying such unit.
In
addition, if (x) the Company issues additional Class A ordinary shares or equity linked securities for capital raising purposes in connection
with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary
share (with such issue price or effective issue price to be determined in good faith by the Board and, in the case of any such issuance
to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such
affiliates, as applicable, prior to such issuance including any transfer or reissuance of such shares (the “Newly Issued Price”)),
(y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest, available for
the funding of the initial Business Combination, and (z) the volume-weighted average trading price of the Class A ordinary shares during
the ten (10) trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination
is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher
of the market value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices adjacent to “Redemption
of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00.” and “Redemption
of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $18.00.” will be adjusted (to
the nearest cent) to be equal to 100% and 180% of the higher of the market value and the Newly Issued Price, respectively.
The
Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation
to settle such warrant exercise unless a registration statement under the Securities Act with respect to Class A ordinary shares
underlying the warrants is then effective and a prospectus is current. No warrant will be exercisable and the Company will not be obligated
to issue Class A ordinary shares upon exercise of a warrant unless Class A ordinary shares issuable upon such warrant exercise
has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of
the warrants. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is
not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for
the unit solely for the Class A ordinary shares underlying such unit.
Redemptions
of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00.
Once
the warrants become exercisable, the Company may call the warrants for redemption (except as described herein with respect to the
Private Placement Warrants):
| ● | in whole and not in part; |
| | |
| ● | at a price of $0.01 per warrant; |
| | |
| ● | upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and |
| | |
| ● | if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the “Reference Value”). |
Redemptions
of warrants for cash when the price per Class A ordinary share equals or exceeds $10.00.
Once
the warrants become exercisable, the Company may call the warrants for redemption (except as described herein with respect to the
Private Placement Warrants):
| ● | in whole and not in part; |
| | |
| ● | at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; provided that during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table in the registration statement, based on the redemption date and the “fair market value” of the Class A ordinary shares (as defined below) except as otherwise described below; provided, further, that if the warrants are not exercised on a cashless basis or otherwise during such 30 day period, the Company shall redeem such warrants for $0.10 per share; |
| | |
| ● | if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and |
| | |
| ● | if the Reference Value is less than $18.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants. |
The
“fair market value” of the Class A ordinary shares shall mean the volume-weighted average price of the Class A ordinary shares
for the ten (10) trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. This
redemption feature differs from the typical warrant redemption features used in other blank check offerings. The Company will provide
the warrant holders with the final fair market value no later than one business day after the 10-day trading period described above ends.
In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 Class A ordinary shares per
warrant (subject to adjustment).
Note
4 — Private Placement
Simultaneously
with the closing of the IPO, the Sponsor purchased an aggregate of 5,466,667 Private Placement Warrants at a price of $1.50 per Private
Placement Warrant, for an aggregate purchase price of $8,200,000, in a private placement. A portion of the proceeds from the private
placement was added to the proceeds from the IPO held in the Trust Account.
Each
of the Private Placement Warrants are identical to the warrants sold as part of the Units in the IPO except that, so long as they are
held by the Sponsor or its permitted transferees: (1) they will not be redeemable by the Company; (2) they (including the Class A ordinary
shares issuable upon exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold by
the Sponsor until 30 days after the completion of the initial Business Combination; (3) they may be exercised by the holders on a cashless
basis; and (4) they (including the Class A ordinary shares issuable upon exercise of these warrants) are entitled to registration rights.
If
the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless.
Note
5 — Related Party Transactions
Founder
Shares
On
November 23, 2020, an executive officer of the Company purchased 8,625,000 shares of the Company’s Class B ordinary shares for
$25,000, or approximately $0.003 per share, in connection with formation (the “Founder Shares”). On December 23, 2020, such
8,625,000 shares of the Company’s Class B ordinary shares were transferred to the Sponsor for $25,000. The Founder Shares included
an aggregate of up to 1,125,000 shares subject to forfeiture if the over-allotment option was not exercised by the underwriters in full.
On January 29, 2021, the underwriters partially exercised their over-allotment option, hence, 250,000 Founder Shares were no longer subject
to forfeiture, and on March 1, 2021, the remaining 875,000 Founder Shares were forfeited by the Sponsor.
The
Sponsor, officers and directors have agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of
(i) one year after the date of the consummation of the initial Business Combination or (ii) subsequent to the initial Business Combination,
(x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share
capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing
at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share
exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their
ordinary shares for cash, securities or other property.
Promissory
Note — Related Party
In
November 2020, the Company issued an unsecured promissory note to an executive officer of the Company. This loan was non-interest bearing,
unsecured and due at the earlier of December 31, 2021 or the closing of the IPO. On December 31, 2020, the amount borrowed under the
note was $1,300. During the period from January 1, 2021 to January 28, 2021, an additional $88,540 was borrowed under the promissory
note, and on January 29, 2021, the balance of $89,840 repaid in full from the proceeds of the IPO, and is no longer available to
be drawn upon.
On
February 23, 2021, the Company issued an unsecured promissory note (the “2021 Note”) in the amount of up to $699,999 to
certain affiliates of the Old Sponsor. The proceeds of the 2021 Note, which may be drawn down from time to time until the Company consummates
its initial Business Combination, will be used for general working capital purposes.
The
2021 Note bears no interest and is payable in full upon the earlier to occur of (i) the Termination Date or (ii) the consummation of
the Company’s Business Combination. A failure to pay the principal within five business days of the date specified above or the
commencement of a voluntary or involuntary bankruptcy action shall be deemed an event of default, in which case the 2021 Note may be
accelerated. The affiliates of the Sponsor had the option to convert any unpaid balance of the 2021 Note into Private Placement Warrants
(the “Conversion Warrants”), each warrant exercisable for one ordinary share of the Company at an exercise price of $1.50 per
share. The terms of the Conversion Warrants would be identical to the warrants issued by the Company to affiliates of the Sponsor in
a private placement that was consummated in connection with the Company’s IPO. The affiliates of the Sponsor shall be entitled
to certain registration rights relating to the Conversion Warrants. On May 3, 2021, the 2021 Note was amended to remove the option to
convert any unpaid balance of the 2021 Note into Private Placement Warrants. As of September 30, 2024 and December 31, 2023, there
were no amounts outstanding under the 2021 Note.
During
the year ended December 31, 2022, the Company issued a number of unsecured promissory notes (the “2022 Notes”) totaling $258,780
to certain executive officers and affiliates of the Company. The proceeds of the 2022 Notes will be used as general working capital purposes.
The 2022 Notes bear no interest and is payable in full upon the earlier to occur of (i) the Termination Date or (ii) the consummation
of the Company’s Business Combination. Failure to pay the principals within five business days of the date specified above or the
commencement of a voluntary or involuntary bankruptcy action shall be deemed an event of default, in which case the 2022 Notes may be
accelerated. As of September 30, 2024 and December 31, 2023, $227,208 were outstanding under the 2022 Notes.
On
January 30, 2024, the Company issued an unsecured promissory note in the principal amount of $1,660,000 (the “2024 Note”)
to the Sponsor. The 2024 Note does not bear interest and matures upon closing of the Business Combination. In the event that the Company
does not consummate a Business Combination, the 2024 Note will be repaid only from funds held outside of the Trust Account or will be
forfeited, eliminated or otherwise forgiven. As of September 30, 2024, $1,125,000 was outstanding under the 2024 Note.
As
of September 30, 2024 and December 31, 2023, $1,352,208 and $227,208 were outstanding under the promissory notes to the Sponsor, respectively.
Subsequent to September 30, 2024, the Company has borrowed $55,000 for funding the Ninth 2024 Extension of the Company.
Administrative
Support Agreement
As
of January 26, 2021 the Company had agreed, commencing on the date that the Securities of the Company were first listed on NYSE, to pay
the Sponsor up to $10,000 per month for office space, utilities and secretarial and administrative support, and other obligations
of the Sponsor. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying
these monthly fees. For each of the three and nine months ended September 30, 2024 and 2023, the Company recorded $30,000 and $90,000
administrative service fees, respectively. $210,000 and $120,000 are reported as due to related parties in the accompanying condensed
balance sheets as of September 30, 2024 and December 31, 2023, respectively.
Working
Capital Loans
In
order to finance transaction costs in connection with a Business Combination, the Sponsor or any of its affiliates or certain of the
Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital
Loans”). If the Company completes a Business Combination, the Company will repay the Working Capital Loans out of the proceeds
of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the
Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside
the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital
Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination company
at a price of $1.50 per warrant at the option of the lender.
On
January 18, 2023, the Company issued an unsecured promissory note (the “2023 Note”) in the amount of $230,000 to the Sponsor.
The proceeds of the 2023 Note will be used for general working capital purposes. The 2023 Note bears no interest and is payable in full
upon the earlier to occur of (i) the consummation of the Company’s Business Combination or (ii) the date that the winding up of
the Company is effective. A failure to pay the principal within five business days of the date specified above or the commencement of
a voluntary or involuntary bankruptcy action shall be deemed an event of default, in which case the 2023 Note may be accelerated. At
the election of the Sponsor, all or a portion of the unpaid principal amount of the 2023 Note may be converted into warrants of the Company,
at a price of $1.50 per warrant, each warrant exercisable for one Class A ordinary share of the Company. The warrants shall be identical
to the Private Placement Warrants issued to the Sponsor at the time of the Company’s IPO. As of September 30, 2024 and December
31, 2023, $230,000 is outstanding under this 2023 Note.
As disclosed
in the definitive proxy statement filed by the Company with the SEC on December 30, 2022 relating to the Extension Meeting, the Sponsor
agreed that if the 2023 Extension Amendment Proposal is approved, it or one or more of its affiliates, members or third-party designees
will contribute to the Company as a loan, within ten (10) business days of the date of the Extension Meeting, $450,000, to be deposited
into the Trust Account. In addition, in the event the Company does not consummate an initial Business Combination by the Articles Extension
Date, the Lender may contribute to the Company $150,000 as a loan to be deposited into the Trust Account for each of nine one-month extensions
following the Articles Extension Date.
Accordingly,
on January 30, 2023, the Company issued the Extension Note to the Sponsor. The Sponsor funded the initial principal amount of $450,000
on January 30, 2023. The Extension Note does not bear interest and matures upon closing of the Company’s initial Business Combination.
In the event that the Company does not consummate a Business Combination, the Extension Note will be repaid only from amounts remaining
outside of the Trust Account, if any. The proceeds of the Extension Note will be deposited in the Trust Account. At the election of the
payee, $1,270,000 of the total principal amount of the Extension Note may be converted, in whole or in part, at the option of the Lender
into warrants of the Company at a price of $1.50 per warrant, which warrants will be identical to the Private Placement Warrants issued
to the Sponsor at the time of the IPO of the Company. As of September 30, 2024 and December 31, 2023, $2,951,000 and $2,901,000 are outstanding
under this Extension Note, respectively.
The
notes were accounted for using the bifurcation method, and it was determined that the conversion feature was de minimis and was recorded
at par value. As of September 30, 2024 and December 31, 2023, there were $3,181,000 and $3,131,000 of borrowings under the Working
Capital Loans, respectively.
Note
6 — Commitments and Contingencies
Registration
Rights
The
holders of the Founder Shares, Private Placement Warrants, Class A ordinary shares underlying the Private Placement Warrants and warrants
that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private
Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights
pursuant to a registration and shareholder rights agreement to be signed prior to or on the Effective Date of the IPO. The holders of
these Securities are entitled to make up to three demands, excluding short form demands, that the Company registers such Securities.
In addition, the holders have certain “piggyback” registration rights with respect to registration statements filed subsequent
to the completion of a Business Combination and rights to require the Company to register for resale such Securities pursuant to Rule
415 under the Securities Act. In addition, if the Sponsor affiliates acquire shares in the IPO, they would become affiliates (as defined
in the Securities Act) of the Company following the IPO, and the Company would file a registration statement following the IPO to register
the resale of the Public Shares purchased by the Sponsor affiliates (or their nominees) in the IPO. The Sponsor affiliates will not be
subject to any lock-up period with respect to any Public Shares they may purchase. The registration rights agreement does not contain
liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s Securities. The Company
will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting
Agreement
The
underwriters had a 45-day option from the date of the IPO to purchase up to an aggregate of 4,500,000 additional Units at the public
offering price less the underwriting commissions to cover over-allotments, if any. On January 29, 2021, the underwriters partially exercised
the over-allotment option to purchase 1,000,000 Units, and were paid an underwriting discount in aggregate of $6,200,000. As of March
15, 2021, the remaining over-allotment option expired.
Additionally,
the underwriters will be entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO held in the Trust Account,
or $10,850,000, upon the completion of the Company’s initial Business Combination subject to the terms of the underwriting agreement.
Investment
Agreement
On
January 26, 2023, the Company, entered into an Investment Agreement (the “Investment Agreement”) with the Old Sponsor, and
Endurance Constellation, LLC, a Delaware limited liability company (the “Investor”), pursuant to which the Investor agreed
to contribute to the Old Sponsor an aggregate amount in cash equal up to $3,000,000, which amount will be loaned to the Company in accordance
with the Extension Note, in consideration for which, the Sponsor shall issue to the Investor interests in certain equity securities.
In
connection with the closing of the transactions contemplated by the Investment Agreement, on January 26, 2023, the Old Sponsor underwent
a reorganization pursuant to which the limited partners of the Old Sponsor transferred all of their limited partnership interests to
the Sponsor. On January 26, 2023, the Old Sponsor was liquidated pursuant to applicable law by the retirement of the general partner
of the Old Sponsor (the second to last partner of the Old Sponsor) and all Securities held by the Old Sponsor were distributed by operation
of law to its sole remaining limited partner, the Sponsor, following which, on January 30, 2023, control of the Sponsor was transferred
to affiliates of Antarctica Capital Partners, LLC, including Antarctica Endurance Manager, LLC the general partner of the Sponsor.
The
Investment Agreement contains customary representations and warranties of the parties, including, among others, with respect to corporate
organization, corporate authority, and compliance with applicable laws. The representations and warranties of each party set forth in
the Investment Agreement were made solely for the benefit of the other parties to the Investment Agreement, and shareholders of the Company
are not third-party beneficiaries of the Investment Agreement. In addition, such representations and warranties (a) are subject to materiality
and other qualifications contained in the Investment Agreement, which may differ from what may be viewed as material by shareholders
of the Company, (b) were made only as of the date of the Investment Agreement or such other date as is specified in the Investment Agreement
and (c) may have been included in the Investment Agreement for the purpose of allocating risk between the parties rather than establishing
matters as facts. Accordingly, the Investment Agreement is included with this filing only to provide shareholders of the Company with
information regarding the terms of the Investment Agreement, and not to provide shareholders of the Company with any other factual information
regarding any of the parties or their respective businesses.
Letter
Agreement
On
January 30, 2023, the Company, the Old Sponsor, certain officers and directors of the Company, and other parties thereto (the “Insiders,”
and together with the Old Sponsor, the “Letter Agreement Parties”) entered into an amendment to the Letter Agreement to allow
the Old Sponsor to transfer its holdings in the Company, directly or indirectly, to affiliate(s) of Antarctica Capital Partners, LLC
prior to the expiration of the applicable lock-up. In connection with the resignation of certain Insiders, the Letter Agreement Parties
agreed that all Insiders that have resigned from their positions as officers and/or directors of the Company and that no longer hold
Class B ordinary shares shall no longer be parties to the Letter Agreement.
Note
7 — Shareholders’ Deficit
Preference
shares — The Company is authorized to issue a total of 1,000,000 preference shares at par value of $0.0001 each
(the “Preference Shares”). On September 30, 2024 and December 31, 2023, there were no Preference Shares issued or outstanding.
Class
A ordinary shares — The Company is authorized to issue a total of 200,000,000 Class A ordinary shares. On
September 30, 2024 and December 31, 2023, there were 7,600,000 and no shares issued and outstanding, excluding 2,367,684 and
4,493,843 shares subject to possible redemption, respectively.
Class
B ordinary shares — The Company is authorized to issue a total of 20,000,000 Class B ordinary shares. On
January 30, 2024, the Sponsor converted an aggregate of 7,600,000 Class B ordinary shares into Class A ordinary shares on a one-for-one
basis. On September 30, 2024 and December 31, 2023, there were 150,000 and 7,750,000 shares issued and outstanding, respectively.
The
Sponsor, officers and directors have agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of
(i) one year after the date of the consummation of the initial Business Combination or (ii) subsequent to the initial Business Combination,
(x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share
capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing
at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share
exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their
ordinary shares for cash, securities or other property.
The
Founder Shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial
Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal,
in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion
of the IPO, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise
of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation
of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible
into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private
Placement Warrants issued to the Sponsor, officers and directors or any of their affiliates upon conversion of Working Capital Loans.
In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one.
Holders
of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all matters submitted
to a vote of the Company’s shareholders, with each share of ordinary shares entitling the holder to one vote.
Note
8 — Fair Value Measurements
The
following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring
basis at September 30, 2024 and December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized
to determine such fair value:
Description | |
Level | |
September 30, 2024 | | |
Level | | |
December 31, 2023 | |
Liabilities | |
| |
| | |
| | |
| |
Public Warrant Liability | |
2 | |
$ | 194,782 | | |
2 | | |
$ | 196,332 | |
Private Placement Warrant Liability | |
2 | |
$ | 103,047 | | |
2 | | |
$ | 103,867 | |
The
Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liability on the condensed balance
sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented
within change in fair value of warrant liability in the condensed statements of operations.
The
Company established the initial fair value for the Public Warrants on January 29, 2021, the date of the Company’s IPO, using a
Monte Carlo simulation model, and for the Private Placement Warrants on January 29, 2021, using a Black-Scholes model. As of September
30, 2024 and December 31, 2023, the fair value of the Private Placement Warrants was valued utilizing the quoted market price of the
Public Warrants, and the fair value of the Public Warrants by reference to the quoted market price of the Public Warrants. The Public
Warrants and Private Placement Warrants were classified as Level 3 at the initial measurement date. There were no transfers among fair
value hierarchy during the three and nine months ended September 30, 2024. The Public Warrants are classified as Level 2 due to the lack
of trading activity as of the reporting date. The estimated fair value of the Public Warrants transferred from a Level 1 measurement
to a Level 2 fair value measurement during the nine months ended September 30, 2023 was $289,333.
Note
9 — Subsequent Events
The
Company evaluated subsequent events and transactions that occurred after the condensed balance sheet date up to the date that the condensed
financial statements were issued. Based on this review, other than as described below, the Company determined no events have occurred
that would require adjustments to the disclosures in the condensed financial statements.
On
October 29, 2024, the Company drew additional Extension Funds, as approved by unanimous extension committee resolution, dated October
29, 2024, pursuant to the Extension Note, which Extension Funds the Company deposited into the Trust Account for its public shareholders.
This deposit enabled the Company to approve the Ninth 2024 Extension. The Ninth 2024 Extension was the ninth of eleven one-month extensions
permitted under the Company’s amended and restated memorandum and articles of association and provides the Company with additional
time to complete its initial Business Combination. The note does not bear interest and matures upon closing of the Company’s initial
Business Combination. In the event that the Company does not consummate a Business Combination, the note will be repaid only from amounts
remaining outside of the Trust Account, if any.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
References
to the “Company,” “Constellation Acquisition Corp I,” “our,” “us” or “we”
refer to Constellation Acquisition Corp I. The following discussion and analysis of the Company’s financial condition and results
of operations should be read in conjunction with the unaudited interim condensed financial statements and the notes thereto contained
elsewhere in this Quarterly Report on Form 10-Q (the “Quarterly Report”). Certain information contained in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary
Note Regarding Forward-Looking Statements
This
Quarterly Report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future
events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause
our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as “may,” “should,” “could,” “would,” “expect,”
“plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative
of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited
to, those described in our other SEC filings.
Overview
We
are a blank check company incorporated in Cayman Islands on November 20, 2020. We were formed for the purpose of effecting a Business
Combination.
Our
sponsor is Constellation Sponsor LP, a Delaware limited partnership. The registration statement for the Initial Public Offering was declared
effective on January 26, 2021. On January 29, 2021, we consummated the Initial Public Offering of 31,000,000 Units, at $10.00 per Unit,
generating gross proceeds of $310.0 million, and incurring offering costs of $17,586,741 million, inclusive of $10,850,000 million in
deferred underwriting commissions. On January 26, 2023, our Old Sponsor underwent a reorganization pursuant to which the limited partners
of our Old Sponsor transferred all of their limited partnership interests to the Sponsor. On January 26, 2023, our Old Sponsor was liquidated
pursuant to applicable law by the retirement of the general partner of our Old Sponsor (the second to last partner of our Sponsor) and
all Securities held by our Old Sponsor were distributed by operation of law to its sole remaining limited partner, the Sponsor, following
which, on January 30, 2023, control of the Old Sponsor was transferred to affiliates of Antarctica Capital Partners, LLC, including Antarctica
Endurance Manager, LLC the general partner of the Sponsor.
Simultaneously
with the closing of the Initial Public Offering, we consummated the private placement of 5,466,667 Private Placement Warrants, at a price
of $1.50 per Private Placement Warrant to our Old Sponsor, which are now held by our Sponsor, generating gross proceeds to us of $8.2
million.
Since
the closing of the Initial Public Offering and the Private Placement, $310.00 million ($10.00 per unit) of the net proceeds of the Initial
Public Offering and certain of the proceeds of the Private Placement was placed in the Trust Account and was invested in permitted United
States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended having
a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company
Act that invest only in direct U.S. government treasury obligations. On January 27, 2023, we liquidated the U.S. government treasury
obligations or money market funds held in the Trust Account.
Our
management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale
of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating
a Business Combination.
We
will only have until the Termination Date to complete an initial Business Combination. If we do not complete a Business Combination by
the Termination Date, we will (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible,
but not more than ten business days thereafter, redeem the Public Shares for a per share pro rata portion of the Trust Account, including
interest not previously released to us to fund our working capital requirements (less taxes payable) and (iii) as promptly as possible
following such redemption, dissolve and liquidate the balance of our net assets to our remaining shareholders, as part of our plan of
dissolution and liquidation. Our Sponsor and initial shareholders entered into the Letter Agreement with us, pursuant to which they have
waived their rights to participate in any redemption with respect to their Founder Shares; however, if the initial shareholders or any
of our officers, directors or affiliates acquire ordinary shares in or after the Initial Public Offering, they will be entitled to a
pro rata share of the Trust Account upon our redemption or liquidation in the event we do not complete a Business Combination within
the required time period. In the event of such distribution, it is possible that the per share value of the residual assets remaining
available for distribution (including the Trust Account assets) will be less than the Initial Public Offering price per unit in the Initial
Public Offering.
On
January 27, 2023, we held an extraordinary general meeting of shareholders to amend the Company’s amended and restated memorandum
and articles of association to extend the date by which the Company has to consummate a Business Combination from January 29, 2023 to
April 29, 2023 and to allow the Company, without another shareholder vote, to elect to extend the 2023 Termination Date to consummate
a Business Combination on a monthly basis for up to nine times by an additional one month each time after the 2023 Articles Extension
Date, by resolution of the Board if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination
Date, until January 29, 2024, or a total of up to twelve months after the 2023 Termination Date, unless the closing of the Company’s
Business Combination shall have occurred prior to such date. The shareholders of the Company approved the 2023 Extension Amendment Proposal
at the Extension Meeting and on January 31, 2023, the Company filed the 2023 Articles Amendment with the Registrar of Companies of the
Cayman Islands.
In
connection with the vote at the Extension Meeting, the holders of 26,506,157 Class A ordinary shares of the Company properly exercised
their right to redeem their shares for an aggregate price of approximately $10.167 per share, for an aggregate redemption amount of approximately
$269,485,746. After the satisfaction of such redemptions, the balance in our Trust Account was approximately $46,138,503. On February
13, 2023, a total of $46,600,678.12 (the remaining trust balance), was placed in a U.S.-based trust account at Citibank, N.A., maintained
by Continental Stock Transfer & Trust Company, acting as trustee.
In
connection with the closing of the transactions contemplated by the Investment Agreement, on January 26, 2023, the Old Sponsor underwent
a reorganization pursuant to which the limited partners of the Old Sponsor transferred all of their limited partnership interests to
the Sponsor. On January 26, 2023, the Old Sponsor was liquidated pursuant to applicable law by the retirement of the general partner
of the Old Sponsor (the second to last partner of the Sponsor) and all Securities held by the Old Sponsor were distributed by operation
of law to its sole remaining limited partner, the Sponsor, following which, on January 30, 2023, control of the Old Sponsor was transferred
to affiliates of Antarctica Capital Partners, LLC.
On
December 20, 2023, the Board approved the voluntary delisting of its Class A ordinary shares, Public Warrants and Units from the NYSE,
and on January 16, 2024, the Company began trading its Class A ordinary shares and Units on OTCQX® Best Market under the
symbols “CSTAF” and “CSTUF,” respectively, and its Public Warrants on the OTCQB® Venture Market
under the symbol “CSTWF.”
On
January 29, 2024, the Company held the Shareholder Meeting (A) to amend, by way of special resolution, the Company’s amended and
restated memorandum and articles of association to extend the Termination Date by which the Company has to consummate a Business Combination
from January 29, 2024 to February 29, 2024 and to allow the Company, without another shareholder vote, to elect to extend the Termination
Date to consummate a Business Combination on a monthly basis for up to eleven times by an additional one month each time after the 2024
Articles Extension Date, by resolution of the directors, if requested by the Sponsor, and upon five days’ advance notice prior
to the applicable Termination Date, until January 29, 2025, or a total of up to twelve months after the 2024 Original Termination Date,
unless the closing of a Business Combination shall have occurred prior thereto; and (B) to amend, by way of special resolution, the Company’s
amended and restated memorandum and articles of association to eliminate from the amended and restated memorandum and articles of association
the limitation that the Company may not redeem Class A ordinary shares to the extent that such redemption would result in the Company
having net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended), of
less than $5,000,001 in order to allow the Company to redeem Public Shares irrespective of whether such redemption would exceed the Redemption
Limitation. The shareholders of the Company approved the 2024 Extension Amendment Proposal and the Redemption Limitation Amendment Proposal
at the Shareholder Meeting and on January 30, 2024, the Company filed the 2024 Articles Amendment with the Registrar of Companies of
the Cayman Islands.
In
connection with that vote to approve the 2024 Extension Amendment Proposal and the Redemption Limitation Amendment Proposal, the holders
of 2,126,159 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately
$11.13 per share, for an aggregate redemption amount of approximately $23,671,533. After the satisfaction of such redemptions and receipt
of the initial deposit of $55,000 to the Trust account, the balance in our Trust Account was approximately $26,415,545.
On
January 30, 2024, the Sponsor converted an aggregate of 7,600,000 Class B ordinary shares into Public Shares on a one-for-one basis.
The Sponsor waived any right to receive funds from the Trust Account with respect to the Public Shares received upon such conversion
and acknowledged that such shares will be subject to all of the restrictions applicable to the original Class B ordinary shares under
the terms of the Letter Agreement.
During
2024, the Board of the Company approved the First 2024 Extension on February 29, 2024, and the extension committee of the Board approved
the Second 2024 Extension, Third 2024 Extension, Fourth 2024 Extension, Fifth 2024 Extension, Sixth 2024 Extension, Seventh 2024 Extension,
Eighth 2024 Extension, and Ninth 2024 Extension on March 28, 2024, April 29, 2024, May 29, 2024, June 28, 2024, July 23, 2024, August
23, 2024, September 26, 2024, and October 29, 2024 respectively, resulting in a new Termination Date of November 29, 2024, and the Company
drew an aggregate of $495,000 of Extension Funds pursuant to the 2024 Note. The 2024 Note does not bear interest and matures upon closing
of the Company’s initial Business Combination. In the event that the Company does not consummate a Business Combination, the 2024
Note will be repaid only from amounts remaining outside of the Trust Account, if any.
Liquidity
and Going Concern Consideration
As
of September 30, 2024, the Company had $5,666 in its operating bank account, and a working capital deficit of $5,095,087, net of the
convertible promissory note – related party. Convertible promissory note - related party amounting to $3,181,000 is not expected
to be settled out of the current assets.
Our
liquidity needs to date have been satisfied through loans from the Sponsor to cover for certain operating expenses. In addition, in order
to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of our
officers and directors may, but are not obligated to, provide the Company working capital loans.
As
of September 30, 2024, there was approximately $4,533,208 of borrowings outstanding and $210,000 of related admin fees owed to the Sponsor
under the following promissory notes:
|
● |
During
the year ended December 31, 2022, the Company issued a number of unsecured promissory notes totaling $258,780 to certain executive
officers and affiliates of the Company. The proceeds of the 2022 Notes was used for general working capital purposes. The 2022 Notes
bear no interest and is payable in full upon the earlier to occur of (i) the Termination Date or (ii) the consummation of the Company’s
Business Combination. Failure to pay the principals within five business days of the date specified above or the commencement of
a voluntary or involuntary bankruptcy action shall be deemed an event of default, in which case the 2022 Notes may be accelerated.
As of September 30, 2024 and December 31, 2023, $227,208 is outstanding under the 2022 Notes. |
|
● |
On
January 18, 2023, the Company issued an unsecured promissory note in the amount of $230,000 to the Sponsor. The proceeds of the 2023
Note was used for general working capital purposes. The 2023 Note bears no interest and is payable in full upon the earlier to occur
of (i) the consummation of the Company’s Business Combination or (ii) the date that the winding up of the Company is effective.
A failure to pay the principal within five business days of the date specified above or the commencement of a voluntary or involuntary
bankruptcy action shall be deemed an event of default, in which case the 2023 Note may be accelerated. At the election of the Sponsor,
all or a portion of the unpaid principal amount of the 2023 Note may be converted into warrants of the Company, at a price of $1.50
per warrant, each warrant exercisable for one Class A ordinary share of the Company. The warrants shall be identical to the Private
Placement Warrants issued to the Sponsor at the time of the Company’s IPO. As of September 30, 2024 and December 31, 2023,
$230,000 is outstanding under this 2023 Note. |
|
● |
On
January 30, 2023, the Company issued an unsecured promissory note, in the amount of $3,000,000 to the Sponsor. The Sponsor funded
the initial principal amount of $450,000 on January 30, 2023. The Extension Note does not bear interest and matures upon closing
of the Company’s Business Combination. In the event that the Company does not consummate a Business Combination, the Extension
Note will be repaid only from amounts remaining outside of the Trust Account, if any. The proceeds of the Extension Note was deposited
in the Trust Account. At the election of the payee, $1,270,000 of the total principal amount of the Extension Note may be converted,
in whole or in part, at the option of the lender into warrants of the Company at a price of $1.50 per warrant, which warrants will
be identical to the Private Placement Warrants issued to the Sponsor at the time of the IPO of the Company. As of September 30, 2024
and December 31, 2023, $2,951,000 and $2,901,000 is outstanding under this Extension Note. |
|
● |
On
January 30, 2024, the Company issued the 2024 Note in the amount of $1,660,000 to the Sponsor. The 2024 Note does not bear interest
and matures upon closing of the Business Combination. In the event that the Company does not consummate a Business Combination, the
2024 Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven.
As of September 30, 2024, $1,125,000 is outstanding under the 2024 Note. |
We
cannot provide any assurance that new financing along the lines detailed above will be available to us on commercially acceptable terms,
if at all. Further, we have until the Termination Date to consummate a Business Combination, but we cannot provide assurance that we
will be able to consummate a Business Combination by that date. If a Business Combination is not consummated by the required date, there
will be a mandatory liquidation and subsequent dissolution. In connection with the Company’s assessment of going concern considerations
in accordance with ASU 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,”
the liquidity condition and mandatory liquidation raise substantial doubt about the Company’s ability to continue as a going concern
until the earlier of the consummation of the Business Combination or January 29, 2025, the date the Company is required to liquidate.
These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the
liabilities that might be necessary should the Company be unable to continue as a going concern.
We
intend to complete our Business Combination before the mandatory liquidation date; however, there can be no assurance that we will be
able to consummate any Business Combination by the Termination Date. If the Company’s estimates of the costs of identifying a target
business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so,
the Company may have insufficient funds available to operate its business prior to a Business Combination. Moreover, the Company may
need to obtain additional financing either to complete a Business Combination or because it becomes obligated to redeem a significant
number of its Public Shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur
debt in connection with such Business Combination.
Results
of Operations
Our
entire activity from inception through September 30, 2024 related to our formation, the preparation for the Initial Public Offering,
and since the closing of the Initial Public Offering, the search for a prospective Business Combination. We have neither engaged in any
operations nor generated any revenues to date. We will not generate any operating revenues until after completion of our Business Combination.
We generate non-operating income in the form of interest income and dividends on cash and investments held in the Trust Account. We expect
to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance),
as well as for due diligence expenses.
For
the three months ended September 30, 2024, we had a net income of approximately $38,000, which included interest earned on investments
held in the Trust Account of $310,000, offset by a loss from operations of $245,000 and a loss from the change in fair value of warrant
liabilities of $28,000.
For
the nine months ended September 30, 2024, we had a net loss of approximately $251,000, which included a loss from operations of $1.3
million, offset by interest earned on investments held in the Trust Account of $1.0 million and a gain from the change in fair value
of warrant liabilities of $2,000.
For
the three months ended September 30, 2023, we had a net income of approximately $0.3 million, which included interest earned on investments
held in the Trust Account of $0.5 million and a gain from the change in fair value of warrant liabilities of $0.5 million, offset by
a loss from operations of $0.7 million.
For
the nine months ended September 30, 2023, we had a net income of approximately $0.1 million, which included an interest earned on investments
held in the Trust Account of $2.5 million and a gain from the change in fair value of warrant liabilities of $0.03 million, offset by
loss from operations of $2.4 million.
Contractual
Obligations
We
do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term
liabilities.
Registration
Rights
The
initial shareholders and holders of the Private Placement Warrants will be entitled to registration rights pursuant to a registration
rights agreement. The initial shareholders and holders of the Private Placement Warrants will be entitled to make up to three demands,
excluding short form registration demands, that register such securities for sale under the Securities Act. In addition, these holders
will have “piggy-back” registration rights to include their securities in other registration statements filed by us. We will
bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting
Agreement
We
paid an underwriting discount of 2% of the per Unit offering price, or approximately $6,200,000 in the aggregate at the closing of the
Initial Public Offering and agreed to pay Deferred Underwriting Fees of 3.5% of the gross offering proceeds, or approximately $10,850,000
in Deferred Underwriting Fees. The Deferred Underwriting Fees will become payable to the underwriters from the amounts held in the Trust
Account solely in the event the Company completes its Business Combination.
Critical
Accounting Estimates
This
management’s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with GAAP. The preparation of these unaudited condensed financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent
assets and liabilities in our unaudited condensed financial statements. On an ongoing basis, we evaluate our estimates and judgments,
including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience,
known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
One of the more significant accounting estimates included in these unaudited condensed financial statements is the determination of the
fair value of the warrant liability. Such estimates may be subject to change as more current information becomes available and, accordingly,
actual results may differ from these estimates under different assumptions or conditions.
Off-Balance
Sheet Arrangements
As
of September 30, 2024, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.
Inflation
We
do not believe that inflation had a material impact on our business, revenues or operating results during the period presented.
JOBS
Act
The
JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify
as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements
based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting
standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such
standards is required for non-emerging growth companies. As a result, the financial statements may not be comparable to companies that
comply with new or revised accounting pronouncements as of public company effective dates.
Additionally,
we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject
to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions
we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over
financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth
public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted
by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report
providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain
executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s
compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our
Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.
Item
3. Quantitative and Qualitative Disclosures About Market Risk.
On
January 27, 2023, we liquidated the U.S. government treasury obligations or money market funds held in the Trust Account. The funds in
the Trust Account will be maintained in cash in an interest-bearing demand deposit account at a bank until the earlier of our initial
Business Combination or our liquidation. Interest on such deposit account is currently approximately 2.5% - 3.0% per anum, but such deposit
account carries a variable rate, and we cannot assure you that such rate will not decrease or increase significantly.
Item
4. Controls and Procedures.
Evaluation
of Disclosure Controls and Procedures
Disclosure
controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed
under the Exchange Act is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and
forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to
our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding
required disclosure.
Under
the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting
officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter
ended September 30, 2024, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation,
our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this
Quarterly Report, our disclosure controls and procedures were effective. Accordingly, management believes that the financial statements
included in this Quarterly Report present fairly in all material respects our financial position, results of operations and cash flows
for the period presented.
We
do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and
procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there
are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure
controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all
our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
goals under all potential future conditions.
Changes
in Internal Control over Financial Reporting
There
was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2024 covered by this
Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART
II - OTHER INFORMATION
Item
1. Legal Proceedings.
None.
Item
1A. Risk Factors.
Investing
in our ordinary shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together
with all of the other information in this Quarterly Report as well as those risk factors previously disclosed in our Annual Report filed
with the SEC. Any of these factors could result in a material adverse effect on our results of operations or financial condition. Additional
risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We
may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item
3. Defaults upon Senior Securities.
None.
Item
4. Mine Safety Disclosures.
Not
applicable.
Item
5. Other Information.
None.
Item
6. Exhibits.
** |
These
certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing
under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
(1) |
Incorporated
herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on February 2, 2024. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dated:
November 14, 2024 |
By: |
/s/
Jarett Goldman |
|
Name: |
Jarett
Goldman |
|
Title: |
Chief
Financial Officer |
|
|
(Principal
Financial and Accounting Officer) |
NONE
NONE
NONE
false
--12-31
Q3
0001834032
0001834032
2024-01-01
2024-09-30
0001834032
csta:ClassAOrdinarySharesParValue00001PerShareMember
2024-01-01
2024-09-30
0001834032
csta:RedeemableWarrantsEachOneWholeWarrantExercisableForOneShareOfClassAOrdinaryShareAtAnExercisePriceOf1150Member
2024-01-01
2024-09-30
0001834032
csta:UnitsEachConsistingOfOneClassAOrdinaryShareAndOnethirdOfOneRedeemableWarrantMember
2024-01-01
2024-09-30
0001834032
us-gaap:CommonClassAMember
2024-11-14
0001834032
us-gaap:CommonClassBMember
2024-11-14
0001834032
2024-09-30
0001834032
2023-12-31
0001834032
us-gaap:RelatedPartyMember
2024-09-30
0001834032
us-gaap:RelatedPartyMember
2023-12-31
0001834032
us-gaap:CommonClassAMember
2024-09-30
0001834032
us-gaap:CommonClassAMember
2023-12-31
0001834032
us-gaap:CommonClassBMember
2024-09-30
0001834032
us-gaap:CommonClassBMember
2023-12-31
0001834032
2024-07-01
2024-09-30
0001834032
2023-07-01
2023-09-30
0001834032
2023-01-01
2023-09-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2024-07-01
2024-09-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2023-07-01
2023-09-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2024-01-01
2024-09-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2023-01-01
2023-09-30
0001834032
csta:NonRedeemableClassAAndBOrdinarySharesMember
2024-07-01
2024-09-30
0001834032
csta:NonRedeemableClassAAndBOrdinarySharesMember
2023-07-01
2023-09-30
0001834032
csta:NonRedeemableClassAAndBOrdinarySharesMember
2024-01-01
2024-09-30
0001834032
csta:NonRedeemableClassAAndBOrdinarySharesMember
2023-01-01
2023-09-30
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2023-12-31
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-12-31
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001834032
us-gaap:RetainedEarningsMember
2023-12-31
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001834032
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-03-31
0001834032
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001834032
2024-01-01
2024-03-31
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2024-03-31
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2024-03-31
0001834032
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001834032
us-gaap:RetainedEarningsMember
2024-03-31
0001834032
2024-03-31
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2024-04-01
2024-06-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2024-04-01
2024-06-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2024-04-01
2024-06-30
0001834032
us-gaap:RetainedEarningsMember
2024-04-01
2024-06-30
0001834032
2024-04-01
2024-06-30
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2024-06-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2024-06-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001834032
us-gaap:RetainedEarningsMember
2024-06-30
0001834032
2024-06-30
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001834032
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
us-gaap:CommonStockMember
2024-09-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2024-09-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0001834032
us-gaap:RetainedEarningsMember
2024-09-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-12-31
0001834032
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001834032
us-gaap:RetainedEarningsMember
2022-12-31
0001834032
2022-12-31
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001834032
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001834032
2023-01-01
2023-03-31
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-03-31
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001834032
us-gaap:RetainedEarningsMember
2023-03-31
0001834032
2023-03-31
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001834032
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001834032
2023-04-01
2023-06-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-06-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001834032
us-gaap:RetainedEarningsMember
2023-06-30
0001834032
2023-06-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001834032
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001834032
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-09-30
0001834032
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001834032
us-gaap:RetainedEarningsMember
2023-09-30
0001834032
2023-09-30
0001834032
us-gaap:CommonClassAMember
us-gaap:IPOMember
2021-01-29
0001834032
us-gaap:OverAllotmentOptionMember
csta:UnderwritingAgreementMember
2021-01-29
0001834032
us-gaap:IPOMember
2021-01-29
0001834032
us-gaap:IPOMember
2021-01-29
2021-01-29
0001834032
us-gaap:CommonClassAMember
2021-01-29
2021-01-29
0001834032
csta:RedeemableWarrantMember
2021-01-29
0001834032
us-gaap:WarrantMember
us-gaap:CommonClassAMember
2021-01-29
0001834032
us-gaap:PrivatePlacementMember
2024-01-01
2024-09-30
0001834032
us-gaap:PrivatePlacementMember
2024-09-30
0001834032
us-gaap:IPOMember
2024-01-01
2024-09-30
0001834032
us-gaap:IPOMember
2024-09-30
0001834032
2021-01-29
2021-01-29
0001834032
2021-01-29
0001834032
csta:TrustAccountsMember
2024-09-30
0001834032
csta:PublicShareMember
2024-09-30
0001834032
csta:SponsorMember
2023-01-27
2023-01-27
0001834032
2023-01-30
2023-01-30
0001834032
us-gaap:CommonClassAMember
2024-01-01
2024-09-30
0001834032
csta:BusinessCombinationMember
2023-04-01
2023-04-28
0001834032
csta:BusinessCombinationMember
2023-05-01
2023-05-26
0001834032
csta:BusinessCombinationMember
2023-07-03
2023-07-03
0001834032
csta:BusinessCombinationMember
2023-07-01
2023-07-28
0001834032
csta:BusinessCombinationMember
2023-08-01
2023-08-29
0001834032
csta:BusinessCombinationMember
2023-09-01
2023-09-29
0001834032
csta:BusinessCombinationMember
2023-10-01
2023-10-26
0001834032
csta:BusinessCombinationMember
2023-11-01
2023-11-28
0001834032
csta:BusinessCombinationMember
2023-12-01
2023-12-28
0001834032
csta:PublicWarrantsMember
2023-12-01
2023-12-20
0001834032
csta:TwoZeroTwoFourExtensionAmendmentProposalMember
us-gaap:CommonClassAMember
2024-01-01
2024-09-30
0001834032
csta:TwoZeroTwoFourExtensionAmendmentProposalMember
2024-09-30
0001834032
us-gaap:CommonClassBMember
2024-01-30
2024-01-30
0001834032
us-gaap:CommonClassBMember
2024-01-30
0001834032
2024-01-30
0001834032
csta:NonRedeemableClassAOrdinarySharesMember
2024-01-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2024-01-30
0001834032
csta:BusinessCombinationMember
2024-02-01
2024-02-29
0001834032
us-gaap:CommonClassAMember
us-gaap:IPOMember
2024-01-01
2024-09-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2024-09-30
0001834032
csta:RedeemableClassAOrdinarySharesMember
2023-12-31
0001834032
2023-01-01
2023-12-30
0001834032
2023-12-30
0001834032
us-gaap:OverAllotmentOptionMember
2021-01-29
0001834032
csta:RedeemableWarrantMember
2021-01-29
2021-01-29
0001834032
us-gaap:CommonClassAMember
2021-01-29
0001834032
us-gaap:CommonClassAMember
csta:PublicWarrantsMember
2024-09-30
0001834032
csta:InitialBusinessCombinationMember
2024-09-30
0001834032
csta:PublicWarrantsMember
2024-01-01
2024-09-30
0001834032
csta:RedemptionOfWarrantsMember
2024-01-01
2024-09-30
0001834032
us-gaap:WarrantMember
2024-01-01
2024-09-30
0001834032
us-gaap:WarrantMember
2024-09-30
0001834032
csta:PrivatePlacementsWarrantMember
2024-09-30
0001834032
csta:PrivatePlacementsWarrantMember
2024-01-01
2024-09-30
0001834032
us-gaap:CommonClassBMember
2020-11-23
2020-11-23
0001834032
us-gaap:CommonClassBMember
2020-11-23
0001834032
us-gaap:CommonClassBMember
2020-12-23
2020-12-23
0001834032
us-gaap:OverAllotmentOptionMember
2021-01-29
2021-01-29
0001834032
csta:FounderSharesMember
2021-03-01
2021-03-01
0001834032
us-gaap:CommonClassAMember
csta:InitialBusinessCombinationMember
2024-01-01
2024-09-30
0001834032
csta:BusinessCommencingMember
2024-01-01
2024-09-30
0001834032
csta:InitialBusinessCombinationMember
2024-01-01
2024-09-30
0001834032
csta:UnsecuredPromissoryNoteMember
2020-12-31
0001834032
csta:UnsecuredPromissoryNoteMember
2021-01-28
0001834032
csta:UnsecuredPromissoryNoteMember
2021-01-29
2021-01-29
0001834032
csta:UnsecuredPromissoryNoteMember
2021-02-23
2021-02-23
0001834032
csta:PrivatePlacementWarrantsMember
2024-09-30
0001834032
srt:ChiefExecutiveOfficerMember
csta:UnsecuredPromissoryNoteMember
2022-01-01
2022-12-31
0001834032
csta:TwoThousandTwentyTwoNotesMember
us-gaap:RelatedPartyMember
2024-09-30
0001834032
csta:TwoThousandTwentyTwoNotesMember
us-gaap:RelatedPartyMember
2023-12-31
0001834032
csta:UnsecuredPromissoryNoteMember
csta:SponsorMember
2024-01-30
2024-01-30
0001834032
csta:UnsecuredPromissoryNoteMember
2024-01-01
2024-09-30
0001834032
csta:UnsecuredPromissoryNoteMember
csta:SponsorMember
2024-09-30
0001834032
csta:UnsecuredPromissoryNoteMember
csta:SponsorMember
2023-12-31
0001834032
2021-01-26
2021-01-26
0001834032
csta:SponsorMember
2023-01-18
2023-01-18
0001834032
us-gaap:WarrantMember
csta:TwothousandtwentythreeNoteMember
2023-01-18
0001834032
csta:TwothousandtwentythreeNoteMember
2024-09-30
0001834032
csta:TwothousandtwentythreeNoteMember
2023-12-31
0001834032
csta:TwoZeroTwoThreeExtensionAmendmentProposalMember
2024-09-30
0001834032
csta:PrivatePlacementWarrantsMember
2023-01-30
0001834032
us-gaap:IPOMember
2023-12-31
0001834032
us-gaap:IPOMember
csta:UnderwritingAgreementMember
2024-09-30
0001834032
us-gaap:OverAllotmentOptionMember
csta:UnderwritingAgreementMember
2021-01-29
2021-01-29
0001834032
csta:SponsorMember
2023-01-26
2023-01-26
0001834032
csta:SponsorMember
2024-01-30
2024-01-30
0001834032
csta:PublicWarrantLiabilityMember
us-gaap:FairValueInputsLevel2Member
2024-09-30
0001834032
csta:PublicWarrantLiabilityMember
us-gaap:FairValueInputsLevel2Member
2023-12-31
0001834032
csta:PrivateWarrantLiabilityMember
us-gaap:FairValueInputsLevel2Member
2024-09-30
0001834032
csta:PrivateWarrantLiabilityMember
us-gaap:FairValueInputsLevel2Member
2023-12-31
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure